NCCN VERSION 2 2015

174 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-99
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
breast cancer: Follow-up analysis from the FIRST study [abstract]. San
Antonio Breast Cancer Symposium 2010:Abstract S1-3. Available at:
440. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant,
formerly ICI 182,780, is as effective as anastrozole in postmenopausal
women with advanced breast cancer progressing after prior endocrine
treatment. J Clin Oncol 2002;20:3396-3403. Available at:
.
441. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized
trial comparing the efficacy and tolerability of fulvestrant versus
anastrozole in postmenopausal women with advanced breast cancer
progressing on prior endocrine therapy: results of a North American
trial. J Clin Oncol 2002;20:3386-3395. Available at:
442. Robertson JFR, Osborne CK, Howell A, et al. Fulvestrant versus
anastrozole for the treatment of advanced breast carcinoma in
postmenopausal women: a prospective combined analysis of two
multicenter trials. Cancer 2003;98:229-238. Available at:
.
443. Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with
advanced breast cancer after progression on prior aromatase inhibitor
therapy: North Central Cancer Treatment Group Trial N0032. J Clin
Oncol 2006;24:1052-1056. Available at:
.
444. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized
placebo controlled trial of fulvestrant compared with exemestane after
prior nonsteroidal aromatase inhibitor therapy in postmenopausal
women with hormone receptor-positive, advanced breast cancer: results
from EFECT. J Clin Oncol 2008;26:1664-1670. Available at:
.
445. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the
CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant
500 mg in postmenopausal women with estrogen receptor-positive
advanced breast cancer. J Clin Oncol 2010;28:4594-4600. Available at:
.
446. Leo AD, Jerusalem G, Petruzelka L, et al. Final analysis of overall
survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250
mg [abstract]. Cancer Res 2012;72 ( Suppl_24):Abstract S1-4 Available
at:
eetingAbstracts/S1-4.
447. Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an open-label
randomized phase III study of fulvestrant and anastrozole in
combination compared with anastrozole alone as first-line therapy for
patients with receptor-positive postmenopausal breast cancer. J Clin
Oncol 2012;30:1919-1925. Available at:
.
448. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole
and fulvestrant in metastatic breast cancer. N Engl J Med
2012;367:435-444. Available at:
.
449. Johnston S, Kilburn LS, Ellis P, et al. Fulvestrant alone or with
concomitant anastrozole Vs exemestane following progression on non-
steroidal aromatase inhibitor – First results of the SoFEa Trial
[abstract]. European Journal of Cancer 2012;48, Supplement 3:Abstract
S2. Available at:
450. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter,
double-blind, randomized study of letrozole, an aromatase inhibitor, for
advanced breast cancer versus megestrol acetate. J Clin Oncol
2001;19:3357-3366. Available at:
.
451. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus
megestrol acetate in the treatment of postmenopausal women with
advanced breast carcinoma: results of a survival update based on a